A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Part of paid clinical trials in Anchorage, Alaska.
- Sponsor
- Amgen
- Study ID
- NCT06072482
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 100 Years
- Healthy Volunteers
- Not accepted
Interventions
- Avacopan — DRUGAdministered orally.
- Placebo — DRUGAdministered orally.
- Standard of Care — DRUGAll participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
Study Details
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Key Dates
- Start date
- Feb 7, 2024
- Status verified
- May 2026
- Primary completion
- Dec 31, 2036
- Completion
- Dec 31, 2036
Study Design
- Enrollment
- 300 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group A: Avacopan + Standard of Care (SoC)Avacopan 30 mg twice daily for 5 years + SoC background immunosuppressive therapy.
- Experimental: Group B: Avacopan/Placebo + SoCAvacopan 30 mg twice daily for 1 year, followed by placebo twice daily for 4 years + SoC background immunosuppressive therapy.
- Placebo Comparator: Group C: Placebo + SoCPlacebo twice daily for 5 years + SoC background immunosuppressive therapy.
Primary Outcome Measure
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to Month 60 ]
Central Contacts
- Amgen Call Center866-572-6436
Locations (60)
Find similar trials in Anchorage, AK
Related Studies
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)PHASE1/PHASE2 · Recruiting · Nkarta, Inc. · Orange, California
- CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated VasculitisPHASE1/PHASE2 · Recruiting · Marcela V. Maus, M.D.,Ph.D. · Boston, Massachusetts